Good news-MS drugs taken while breastfeeding may not affect child development.

A preliminary study presented at the American Academy of Neurology's 76th Annual Meeting suggests that certain medications for multiple sclerosis (MS) called monoclonal antibodies, taken while breastfeeding, may not have a negative impact on a child's development during the first three years of life. The study examined four monoclonal antibodies for MS: natalizumab, ocrelizumab, rituximab, and ofatumumab. Researchers found no differences in the health or development of infants exposed to these medications through breastfeeding compared to infants not exposed. However, the study's results for the third year of life are less meaningful due to a limited follow-up period. [Extracted from the article]